Lv41
758 积分 2022-08-31 加入
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
8小时前
已完结
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
8小时前
已完结
Twenty‐year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors
15天前
已完结
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
27天前
已完结
KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
1个月前
已完结
Unlocking the potential of T cell engagers in solid tumors
3个月前
已完结
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
4个月前
已完结
Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics
4个月前
已完结
Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins
4个月前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
5个月前
已完结
皖公网安备34019202002308
